NEW DELHI, Nov 1: The ICMR has sought collaboration with Indian industry partners for manufacturing indigenously developed monoclonal antibodies for treating deadly Nipah Virus following the successful animal trials to ensure their timely access during outbreaks.

Monoclonal antibodies are laboratory-made proteins that mimic the antibodies produced by the immune system to protect against foreign substances and harmful pathogens.

The Nipah virus (NiV), which has an extremely high fatality rate, has emerged as one of the most significant zoonotic threats to India, with repeated outbreaks recorded since 2001, according to the Expression of Interest (EoI) document issued by the Indian Council of Medical Research (ICMR).

The apex health research body has issued an EoI stating: “The ICMR is wi

See Full Page